S
Sorriso Pharmaceuticals
A biotech firm developing disease-modifying antibodies for the treatment of inflammatory diseases
About Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2020, concentrating on the development of disease-modifying antibodies for immune-mediated inflammatory diseases. The company was founded by Ciara Kennedy, who serves as President and CEO. Dr. Kennedy has a track record of advancing therapeutic programs and previously led Amplyx Pharmaceuticals until its acquisition by Pfizer. The company officially launched in December 2021 with a significant $31 million Series A financing round co-led by New Enterprise Associates (NEA) and Arix Bioscience plc. This initial funding was aimed at progressing its pipeline of oral antibodies.
The company's core business revolves around its proprietary "Vorabody" platform, which engineers potent, single-domain antibodies for oral delivery. This technology is designed to create durable antibody fragments that remain stable and active within the gastrointestinal tract, allowing for localized treatment of inflammation. This approach targets the combined global market for inflammatory conditions, valued in excess of $50 billion. The business model focuses on developing these therapies through clinical trials to address unmet needs in patient populations that currently rely on systemic, injectable treatments. The oral delivery method aims to offer comparable efficacy to injections but with improved safety, reduced systemic exposure, and greater patient convenience.
Sorriso's pipeline includes several candidates, with the lead program being SOR102. This oral biologic is being developed for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. SOR102 functions as a bispecific antibody that simultaneously inhibits two validated drivers of IBD: TNF-alpha and IL-23. By combining these two mechanisms into a single oral therapy, SOR102 is designed to provide targeted action within inflamed intestinal tissue with minimal systemic absorption. The company initiated a first-in-human Phase 1/1b clinical trial for SOR102 in late 2023 to evaluate its safety and efficacy in patients with ulcerative colitis. In December 2024, Sorriso announced positive results from the Phase 1b trial, with plans to begin a Phase 2 trial in 2025. Other pipeline assets include SOR101 (an oral anti-TNFa) and SOR104 (an anti-IL-7Ra).
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2021 | $31M | $124M | NEA · Arix Bioscience | ↗ |
| SPINOUT✓Other financing | Jan 2020 | $0 | — | Flanders Institute for Biotechnology · Vrije Universiteit Brussel | — |
Growth signals
Latest recorded traffic for Sorriso Pharmaceuticals is 1.3K monthly website visits, down 38.1% over the last three months. Sorriso Pharmaceuticals's team declined 17.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sorriso Pharmaceuticals in the Sandy ecosystem
The Sorriso Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
NEA
Arix Bioscience
Other known investors4 additional known investors
Flanders Institute for Biotechnology
Vrije Universiteit Brussel
Biovision Ventures
Pappas Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sorriso Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sorriso Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










